Astellas Pharma reports data on Xtandi in prostate cancer
Astellas Pharma announced the presentation of new data that "reaffirms the role" of XTANDI in extending time to prostate specific antigen progression in men with advanced prostate cancer. Data from a study examining the efficacy and safety of enzalutamide versus placebo in 409 Asian patients from China, South Korea, Taiwan and Hong Kong with asymptomatic/mildly symptomatic progressive advanced prostate cancer following androgen deprivation therapy found that enzalutamide significantly improved time to PSA progression, compared with placebo -- 7.46 months vs 2.86 months. Secondary end points included overall survival, defined as time from randomisation to death from any cause, and radiographic progression free survival. Although the median overall survival was not yet reached at the time of the data cut-off in either treatment arm, enzalutamide significantly reduced the risk of death. At data cut-off, enzalutamide significantly reduced the risk of rPFS events with 19.6% of patients receiving enzalutamide and 36% of patients in the placebo arm experiencing a rPFS event. While slightly more patients treated with enzalutamide reported at least one treatment-emergent adverse event, enzalutamide was generally well tolerated in the trial.